Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 18/20 | 0.56 |
| ▸ | DAGLA | Q9Y4D2 | 14/20 | 0.53 |
| ▸ | CES1 | P23141 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963517 | 0.80 | FAAH (0.62) | FAAHDAGLACES1 | |
| SCHEMBL5422144 | 0.73 | FAAH (0.59) | FAAHDAGLACES1 | |
| SCHEMBL6634876 | 0.73 | FAAH (0.60) | FAAHDAGLACES1 | |
| SCHEMBL11643069 | 0.73 | DAGLA (0.60) | FAAHDAGLACES1 | |
| SCHEMBL10220689 | 0.73 | NPC1 (0.46) | FAAHDAGLA | |
| SCHEMBL3961770 | 0.71 | FAAH (1.00) | FAAHDAGLACES1 | |
| Trifluoroacetic Acid SCHEMBL30413710 | 0.71 | NPC1 (0.46) | FAAHDAGLACES1 | |
| SCHEMBL3618162 | 0.71 | NPC1 (0.42) | FAAHDAGLA | |
| SCHEMBL3963662 | 0.70 | FAAH (1.00) | FAAHDAGLACES1 | |
| SCHEMBL38656136 | 0.70 | FAAH (0.45) | FAAHDAGLACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8840866-B2 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | FAAH 602/4885DAGLA 1772/4885CES1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.